Endometrial Cancers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated With a New Small Tyrosine Kinase Inhibitor in an Orthotopic Mouse Model
Conclusions
AL3818 shows superior efficacy for the treatment of endometrial cancer irresponsive to conventional carboplatin and paclitaxel combination and warrants further investigation.
Source: International Journal of Gynecological Cancer - Category: Cancer & Oncology Tags: Uterine Cancer Source Type: research
More News: Cancer | Cancer & Oncology | Cancer of the Uterus | Endometrial Cancer | Oral Cancer | Stem Cell Therapy | Stem Cells | Study